疫苗安全性评估:评估获益与风险的实践方面
疫苗面向大量健康人群(含婴幼儿)接种,对潜在风险耐受度低,且免疫规划的长期获益可能因疾病消失而使人松懈,欧洲与美国麻疹疫情显示覆盖率下降后疾病即重现。无根据的疫苗恐慌(如麻腮风联合疫苗与自闭症、全细胞百日咳疫苗与脑病)可导致接种率下降和疾病复燃。疫苗安全性评估从非临床到上市后持续进行,多机构多层面评估增强了对风险调查与管理的信心。
要点
- 疫苗面向大量健康人群,对潜在风险或副作用耐受度低。
- 覆盖率下降后麻疹等疾病会立即重现。
- 无根据的疫苗恐慌可致接种率下降与疾病复燃。
核心结论
- 疫苗安全性评估是全面且持续的,从组分纯度、稳定性与无菌性的非临床评价开始,贯穿临床开发阶段和整个使用期包括上市后。
- 多个独立机构在多个层面开展的安全性评估的广度与深度增强了对任何潜在风险或副作用被严格调查和管理的信心。
- 所有相关方的最终目标是确保疫苗具有有利的获益-风险特征。
研究设计与样本
- 原文为综述,未报告系统检索范围。
主要发现
- 疫苗与多数药物不同,面向大量且主要为健康的人群接种,包括婴幼儿和儿童,因此对潜在风险或副作用的耐受度低。
- 免疫接种在减少或消除传染病方面的长期获益可能因病例消失而使人自满,但欧洲和美国近期麻疹疫情表明,一旦疫苗覆盖率下降,疾病就会重现。
- 将麻腮风联合疫苗与自闭症、全细胞百日咳疫苗与脑病相联系的无根据疫苗恐慌可产生巨大影响,导致疫苗接种减少和疾病复燃。
- 行业、监管机构、学术界、医学界和公众均在监测疫苗安全中发挥作用。
- 在利益相关方中,医疗专业人员和疫苗提供者在免疫接种后不良事件(AEFI)的预防、识别、调查和管理中具有关键作用。
关键数值与推荐
- 指南和算法有助于判断AEFI可能由疫苗引起还是与疫苗巧合。
- 鼓励医疗提供者严格调查AEFI并通过当地报告流程报告。
临床怎么用
- 医疗专业人员和疫苗提供者在AEFI的预防、识别、调查和管理中具有关键作用。
- 鼓励医疗提供者严格调查AEFI并通过当地报告流程报告。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccines are different from most medicines in that they are administered to large and mostly healthy populations including infants and children, so there is a low tolerance for potential risks or side-effects. In addition, the long-term benefits of immunisation in reducing or eliminating infectious diseases may induce complacency due to the absence of cases. However, as demonstrated in recent measles outbreaks in Europe and United States, reappearance of the disease occurs as soon as vaccine coverage falls. Unfounded vaccine scares such as those associating the combined measles-mumps-rubella vaccine with autism, and whole-cell pertussis vaccines with encephalopathy, can also have massive impacts, resulting in reduced vaccine uptake and disease resurgence. The safety assessment of vaccines is exhaustive and continuous; beginning with non-clinical evaluation of their individual components in terms of purity, stability and sterility, continuing throughout the clinical development phase and entire duration of use of the vaccine; including post-approval. The breadth and depth of safety assessments conducted at multiple levels by a range of independent organizations increases confidence in the rigour with which any potential risks or side-effects are investigated and managed. Industry, regulatory agencies, academia, the medical community and the general public all play a role in monitoring vaccine safety. Within these stakeholder groups, the healthcare professional and vaccine provider have key roles in the prevention, identification, investigation and management of adverse events following immunisation (AEFI). Guidelines and algorithms aid in determining whether AEFI may have been caused by the vaccine, or whether it is coincidental to it. Healthcare providers are encouraged to rigorously investigate AEFIs and to report them via local reporting processes. The ultimate objective for all parties is to ensure vaccines have a favourable benefit-risk profile.
引用
- Di Pasquale A, Bonanni P, Garçon N, et al. Vaccine safety evaluation: Practical aspects in assessing benefits and risks. Vaccine. 2016. PMID: 27836435. doi:10.1016/j.vaccine.2016.10.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。